



Date: 03/08/2021.

To,
The Manager
Listing Compliance Department,
BSE Limited (Bombay Stock Exchange Limited),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Ref : Script Id "BAJAJHCARE", Script Code "539872".

Sub : Outcome of Board Meeting & submission of Unaudited Financial Results for the quarter ended June 30, 2021.

The Board of Directors at its Meeting held today has inter alia:

- Approved the unaudited Financial Statements for the quarter ended June 30, 2021, as recommended by the Audit Committee; and

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we enclose the following:

- (i) Unaudited Financial Results for the quarter ended June 30,, 2021 along with limited review report; and

The above information is also available on the Company's website at www.bajajhealth.com. This is for your information and records.

We wish to inform you that Board Meeting commenced today at 01.00 p.m. and concluded at 3.45 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For and on behalf of Board of Directors
of Bajaj Healthcare Limited**

**Mr. Aakashkumar Keshari
Company Secretary**



BAJAJ HEALTHCARE LIMITED

Registered Office : Corp. Off.: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A/1, Road No. 23, Above ICICI Bank, Wagle Ind. Estate, Thane(W)-400604.

• Tel. : +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : www.bajajhealth.com

CIN NO.: L99999MH1993PLC072892

Chaturvedi & Agrawal

Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Bajaj Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter ended June 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards³⁴ "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.


**For Chaturvedi & Agrawal
Chartered Accountants
FRN: 101717W**


Rasik Chaturvedi

Partner

M. no: 039524

UDIN: 21039524AAAAABF1896



Date: August 03, 2021

Place: Thane



BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30th JUNE, 2021
(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Year Ended
	30.06.2021	31.03.2021	30.06.2020	31.03.2021
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from operations	18,568.87	13,218.16	13,983.32	65,698.38
II. Other Income	67.95	215.24	90.17	691.26
III. Total Revenue (I+II)	18,636.83	13,433.39	14,073.49	66,389.64
IV. Expenses				
(a) Cost of materials consumed (Including Other Direct Expenses)	15,444.24	8,728.43	10,388.39	46,342.49
(b) Changes in Inventories of Finished Good	(1,992.56)	(59.94)	(375.67)	70.18
(c) Employee benefits expense	964.34	804.61	798.73	3,454.87
(d) Finance Costs	279.33	215.19	204.81	829.60
(d) Depreciation and amortisation expense	413.07	442.88	376.47	1,612.42
(e) Other expenses	803.05	283.03	637.30	2,198.12
Total Expenses	15,911.47	10,414.19	12,030.04	54,507.67
V. Profit Before Tax	2,725.36	3,019.20	2,043.46	11,881.97
VI. Tax Expense				
(a) Current tax	814.00	697.41	573.40	3,497.41
(b) Earlier Years	(0.09)	23.73	(59.10)	23.73
(c) Deferred Tax	(10.26)	170.27	-	49.93
Total Tax Expenses	803.64	891.41	514.30	3,571.07
VII. Profit (Loss) for the Period	1,921.71	2,127.79	1,529.16	8,310.89
VIII. Other comprehensive Income				
(i) Items that will not be reclassified to profit or loss ^f	-	(30.46)	-	(30.46)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	8.87	-	8.87
(iii) Items that will be reclassified to profit or loss	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Comprehensive Income for the Period	1,921.71	2,106.20	1,529.16	8,289.31
IX. Paid-up Equity Share Capital (Face Value Rs. 10/-)	1,379.92	1,379.92	1,379.92	1,379.92
X. Other Equity excluding Revaluation Reserve	-	-	-	24,444.83
XI. EPS (Not Annualised)				
(a) Basic (in Rs.)	13.93	15.42	11.08	60.23
(b) Diluted (in Rs.)	13.93	15.42	11.08	60.23
Dividend Declared during the Year:				
Interim Dividend (Per Share)	-	-	-	1.25
Special Dividend (Per Share)	-	-	-	0.50
Cumulative Dividend Percentage	-	-	-	17.50%

Note :

- a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 3rd August, 2021.
- b) The financial results for the Quarter 30th June 2021 have been subjected to limited review by the statutory auditors of the Company.
- c) The Statement as per IND AS - 108 on segment reporting is given as Annexure-A.
- d) The figures for the quarter ended March 31, 2021 represent the derived figures between the audited figures in respect of the full financial year ended March 31, 2021 and the unaudited published year-to-date figures up to December 31, 2020, being the date of the end of third quarter of the financial year, which were subjected to a limited review by the statutory auditor of the company.
- e) The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners. The Management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, inventory, based on the information available to date, both internal and external, while preparing the company's financial results for the quarter ended 30th June 2021.
- f) Figures of previous period have been regrouped/reclassified, wherever necessary, to make them comparable and to conform with current period classification.

By Order of the Board
For Bajaj Healthcare Limited

Date: 03rd August 2021
Place: Thane

Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER ENDED ON 30th JUNE, 2021

Annexure : A

(Rs. In Lakhs)

S r	Particulars	Quarter Ended			Year Ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
A	Segment Revenue (Excluding Intersegment Revenue)				
	Bulk Drugs	13528.72	12723.88	12568.26	59336.46
	Formulations	5040.16	494.28	1415.06	6361.92
	Total	18,568.87	13,218.16	13,983.32	65,698.38
	InterSegment Revenue				
	Bulk Drugs	4422.16	271.17	783.46	2,586.87
	Formulations	615.12	170.10	3.54	210.83
	Total	5,037.28	441.27	787.01	2,797.69
	Gross Segment Revenue (Including Intersegment Revenue)				
	Bulk Drugs	17950.88	12995.05	13351.73	61923.32
	Formulations	5655.27	664.38	1418.60	6572.75
	Total	23,606.15	13,659.43	14,770.33	68,496.07
B	II. Segment Results				
	Profit / (Loss) Before Tax & Finance Cost				
	Bulk Drugs	3495.49	3,445.83	2,746.60	13,924.25
	Formulations	312.25	11.99	127.05	985.43
	Total	3,807.74	3,457.82	2,873.65	14,909.68
	Less : Interest	279.33	215.19	204.81	829.60
	Other Unallocable Expenditure (Net)	803.05	223.43	625.38	2,198.12
	Total Profit Before Tax	2,725.36	3,019.20	2,043.46	11,881.97
C	I. Segment Assets				
	Bulk Drugs	55,247.77	50,063.51	37,912.63	50,063.51
	Formulations	4,991.22	2,499.35	2,547.92	2,499.35
	Others	0.31	0.31	500.31	0.31
	Total	60,239.29	52,563.17	40,960.86	52,563.17
	II. Segment Liabilities				
	Bulk Drugs	30,264.51	25,743.74	20,096.23	25,743.74
	Formulations	1,683.63	484.92	591.27	484.92
	Others	528.39	493.46	958.62	493.46
	Total	32,476.53	26,722.12	21,646.12	26,722.12
	Total Capital Employed	27,762.76	25,841.05	19,314.74	25,841.05
	Total (II+III)	60,239.29	52,563.17	40,960.86	52,563.17

By Order of the Board
For Bajaj Healthcare Limited



Place : Thane
Date: 03rd August 2021

Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director